In-article:

Genomic Vision announces the approval by its AGM of all the resolutions supported by the Management Board – 05/23/2022 at 7:00 p.m.


The EGM adopted all of the proposed resolutions, with the exception of the 21st resolution which was rejected in accordance with the recommendations of the Management Board.

The meeting notably approved the establishment of a new line of financing with Winance through the reserved issue of OCABSA for a maximum amount of €28.8 million (€30 million nominal value). This issue was the subject of a prospectus approved by the Autorité des marchés financiers (AMF) on May 20, 2022 under approval number 22-170, consisting of the universal registration document filed on April 14, 2022, under number D.22-0293, of the amendment to the universal registration document filed on May 20, 2022 under number D.22-0293-A01, of a securities note and a summary, and available at registered office of the Company (80/84 Rue des Meuniers, 92220 Bagneux), on the Company’s website (www.genomicvision.com) and on that of the AMF (www.amf-france.org). This approval by the AMF should not be considered as a favorable opinion on the issuer and on the quality of the financial securities covered by the prospectus. Investors are invited to make their own assessment as to the advisability of investing in the financial securities concerned.



Source link -86